Dapagliflozin Reduces CV Death, Heart Failure Worsening in HFpEF Patients
The placebo-controlled, event-driven DELIVER study included 6263 patients.
The placebo-controlled, event-driven DELIVER study included 6263 patients.
Researchers used 2018 data from the National Health Interview Survey to investigate the association.
The PRESIDE trial included 687 chemotherapy-naïve patients with mCRPC who had progressive disease while on androgen deprivation therapy or following bilateral orchiectomy.
The analysis included 4919 patients, of which 19.7% (n=969) had received a lipophilic statin and 9.2% (n=452) had received a hydrophilic statin.
The EMPA-KIDNEY study enrolled more than 6600 patients with CKD attributable to a wide range of underlying causes.
The CRL stated that the application for bardoxolone could not be approved in its current form due to a lack of data supporting claims of slowing kidney function loss and reducing kidney failure progression.
Findings from an ongoing randomized, placebo-controlled, observer-blind phase 3 trial showed Spikevax was 93.2% effective at preventing COVID-19.
Concise drug information for molnupiravir and Paxlovid; the FDA granted Emergency Use to both oral antiviral therapies.
The researchers examined data from the National Health and Nutrition Examination Survey.
The CDC is recommending that health care providers take a travel history for all suspected and confirmed cases of COVID-19.